Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

ABSTRACT:

Background

BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers.

Methods

We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival.

Results

In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 mo

SUBMITTER: Hyman DM 

PROVIDER: S-EPMC4971773 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature